PROGNOSTIC FACTORS IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR MULTIPLE-MYELOMA

被引：237

作者：

GAHRTON, G ^{[1
]}

TURA, S ^{[1
]}

LJUNGMAN, P ^{[1
]}

BLADE, J ^{[1
]}

BRANDT, L ^{[1
]}

CAVO, M ^{[1
]}

FACON, T ^{[1
]}

GRATWOHL, A ^{[1
]}

HAGENBEEK, A ^{[1
]}

JACOBS, P ^{[1
]}

DELAURENZI, A ^{[1
]}

VANLINT, M ^{[1
]}

MICHALLET, M ^{[1
]}

NIKOSKELAINEN, J ^{[1
]}

REIFFERS, J ^{[1
]}

SAMSON, D ^{[1
]}

VERDONCK, L ^{[1
]}

DEWITTE, T ^{[1
]}

VOLIN, L ^{[1
]}

机构：

[1] EUROPEAN GRP BLOOD & MARROW TRANSPLANTAT,HUDDINGE,SWEDEN

来源：

JOURNAL OF CLINICAL ONCOLOGY | 1995年 / 13卷 / 06期

关键词：

D O I：

10.1200/JCO.1995.13.6.1312

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: To analyze prognostic factors for allogeneic bone marrow transplantation (BMT) in multiple myeloma. Patients and Methods: One hundred sixty-two reports of allogeneic matched sibling-donor transplants in multiple myeloma received by the European Group for Blood and Marrow Transplantation (EBMT) registry between 1983 and early 1993 were analyzed for prognostic factors. End points were complete remission, survival, and duration of complete remission. Results: Following BMT, 44% of all patients and 60% of assessable patients entered complete remission. The overall actuarial survival rate was 32% at 4 years and 28% at 7 years. The overall relapse-free survival rate of 72 patients who were in complete remission after BMT was 34% at 6 years. Favorable pretransplant prognostic factors for survival were female sex (41% at 4 years), stage I disease at diagnosis (52% at 4 years), one line of previous treatment (42% at 4 years), and being in complete remission before conditioning (64% at 3 years). The subtype immunoglobulin A (IgA) myeloma and a low beta(2)-microglobulin lever (< 4 g/L) also tended to have a favorable prognostic impact. The most important posttransplant prognostic factor was to enter a complete remission. Grade III to IV graft-versus-host disease (GVHD) was associated with poor survival. Conclusion: Patients with a low tumor burden who respond to treatment before BMT and are transplanted after first-line therapy have the best prognosis following BMT. (C) 1995 by American Society of Clinical Oncology.

引用

页码：1312 / 1322

页数：11

共 23 条

[11]

GRATWOHL A, 1993, BONE MARROW TRANSPL, V12, P509

[12]

GREIPP PR, 1993, BLOOD, V81, P3382

[13]

HAROUSSEAU JL, 1993, 19TH ANN M EBMT GARM, P68

[14] CHEMOTHERAPY COMPARED WITH BONE-MARROW TRANSPLANTATION FOR ADULTS WITH ACUTE LYMPHOBLASTIC-LEUKEMIA IN 1ST REMISSION [J].

HOROWITZ, MM ;

MESSERER, D ;

HOELZER, D ;

GALE, RP ;

NEISS, A ;

ATKINSON, K ;

BARRETT, AJ ;

BUCHNER, T ;

FREUND, M ;

HEIL, G ;

HIDDEMANN, W ;

KOLB, HJ ;

LOFFLER, H ;

MARMONT, AM ;

MASCHMEYER, G ;

RIMM, AA ;

ROZMAN, C ;

SOBOCINSKI, KA ;

SPECK, B ;

THIEL, E ;

WEISDORF, DJ ;

ZWAAN, FE ;

BORTIN, MM .

ANNALS OF INTERNAL MEDICINE, 1991, 115 (01) :13-18

[15]

HOROWITZ MM, 1990, BLOOD, V75, P555

[16] HLA-IDENTICAL SIBLING DONOR BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA IN 1ST CHRONIC PHASE - INFLUENCE OF GVHD PROPHYLAXIS ON OUTCOME [J].

MARKS, DI ;

HUGHES, TP ;

SZYDLO, R ;

KELLY, S ;

CULLIS, JO ;

SCHWARER, AP ;

MACKINNON, S ;

APPERLEY, J ;

BARRETT, AJ ;

HOWS, JM ;

GOLDMAN, JM .

BRITISH JOURNAL OF HAEMATOLOGY, 1992, 81 (03) :383-390

[17]

OSTERBORG A, 1989, EUR J HAEMATOL, V43, P54

[18]

OSTERBORG A, 1993, BLOOD, V81, P1428

[19] OUTCOME AFTER ALLOGENEIC BONE-MARROW TRANSPLANT FOR LEUKEMIA IN OLDER ADULTS [J].

RINGDEN, O ;

HOROWITZ, MM ;

GALE, RP ;

BIGGS, JC ;

GAJEWSKI, J ;

RIMM, AA ;

SPECK, B ;

VEUMSTONE, JA ;

DEWITTE, T ;

BORTIN, MM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (01) :57-60

[20] A RANDOMIZED TRIAL COMPARING BUSULFAN WITH TOTAL-BODY IRRADIATION AS CONDITIONING IN ALLOGENEIC MARROW TRANSPLANT RECIPIENTS WITH LEUKEMIA - A REPORT FROM THE NORDIC-BONE-MARROW-TRANSPLANTATION-GROUP [J].

RINGDEN, O ;

RUUTU, T ;

REMBERGER, M ;

NIKOSKELAINEN, J ;

VOLIN, L ;

VINDELOV, L ;

PARKKALI, T ;

LENHOFF, S ;

SALLERFORS, B ;

LJUNGMAN, P ;

MELLANDER, L ;

JACOBSEN, N .

BLOOD, 1994, 83 (09) :2723-2730

← 1 2 3 →